Patient ID | Viremic non-progressors (VNP) | Typical progressors (TP) | Rapid progressor (RP) | ||||
---|---|---|---|---|---|---|---|
VNP-1 | VNP-2 | VNP-3 | TP-1 | TP-2 | TP-3 | RP | |
Demographics | |||||||
 Agea | 44 | 50 | 42 | 40 | 43 | 38 | 30 |
 Sexb | M | M | M | M | M | M | M |
 Race | Black | Caucasian | Black | Caucasian | Black | Black | Black |
 Risk Factorc | MSM | Unknown | MSM | MSM | MSM | MSM | MSM |
 Years HIV+d | 14 | 17 | 10 | 14 | 15 | 12 | 5 |
 Follow up (months)e | 84 | 37 | 123 | 35 | 19 | 31 | 18 |
CD4+ (cells/mm3) | |||||||
 CD4+ countf | 563 | 443 | 479 | 386 | 361 | 126 | 11 |
 Mean CD4+ countg | 529 | 445 | 442 | 483 | 457 | 293 | 57 |
 Range CD4+ countg | 372–711 | 316–608 | 280–814 | 220–789 | 361–645 | 126–511 | 11–124 |
 Slope CD4+ counth | −0.6 | −0.7 | −0.4 | −9.6 | −8.2 | −13.1 | −4.7 |
HIV-1 RNA (log 10 copies/ml) | |||||||
 HIV-1 RNAf | 5.46 | 4.90 | 4.70 | 4.41 | 4.27 | 4.49 | 4.64 |
 Mean HIV-1 RNAg | 4.68 | 4.91 | 4.31 | 4.23 | 4.45 | 4.67 | 4.49 |
 Range HIV-1 RNAg | 3.61–5.45 | 4.27–5.08 | 3.62–4.71 | 3.89–4.62 | 4.28–4.62 | 3.90–4.90 | 4.09–4.66 |
Virus characteristics | |||||||
 HIV-1 subtypei | B | B | B | B | B | B | B |
 HIV-1 coreceptor tropismj | R5 | R5 | R5 | R5 | R5 | R5 | D/M |